• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

    2/13/24 9:21:55 PM ET
    $JATT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $JATT alert in real time by email
    SC 13G/A 1 jatt20231231.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
     
     

    Zura Bio Limited (formerly known as JATT Acquisition Corp)

    (Name of Issuer)
     

    Class A Ordinary Shares

    (Title of Class of Securities)
     

    G50752107

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    o Rule 13d-1(c)
    o Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Glazer Capital, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     
     

     

     

    1

    NAME OF REPORTING PERSON

    Paul J. Glazer

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     
     

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Zura Bio Limited (formerly known as JATT Acquisition Corp) (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at PO Box 309, Ugland House, Grand Cayman, Cayman Islands E9 KY1-1104.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and
       
      (ii) Mr. Paul J. Glazer ("Mr. Glazer"), who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds.
       
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.

     

    Item 2(c). CITIZENSHIP:
       
      Glazer Capital is a Delaware limited liability company.  Mr. Glazer is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Class A Ordinary Shares

     

    Item 2(e). CUSIP NUMBER:
       
      G50752107

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     
     

     

      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨

    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ¨

    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

      (e) ý

    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) ý

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨

    Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     

      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
       

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
     
     

     

      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its or his knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 13, 2024

     

    GLAZER CAPITAL, LLC    
         
         
    By: /s/ Paul J. Glazer    
    Name: Paul J. Glazer    
    Title: Managing Member    
         
         
    /s/ Paul J. Glazer    
    PAUL J. GLAZER    

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     

     

     

    EXHIBIT I

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

     

    DATED as of February 13, 2024

     

    GLAZER CAPITAL, LLC    
         
         
    By: /s/ Paul J. Glazer    
    Name: Paul J. Glazer    
    Title: Managing Member    
         
         
    /s/ Paul J. Glazer    
    PAUL J. GLAZER    

     

    Get the next $JATT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JATT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JATT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Lisicki Robert

      4 - Zura Bio Ltd (0001855644) (Issuer)

      1/26/24 11:33:20 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Ploos Van Amstel Arnout

      4 - Zura Bio Ltd (0001855644) (Issuer)

      1/26/24 11:32:02 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Thiara Parvinder

      4 - Zura Bio Ltd (0001855644) (Issuer)

      1/26/24 11:30:45 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JATT
    SEC Filings

    See more
    • JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      2/2/24 6:02:07 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      1/11/24 5:25:15 PM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zura Bio Ltd (0001855644) (Filer)

      1/8/24 6:03:32 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JATT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

      Zura Bio Limited to trade on Nasdaq as a clinical-stage biotechnology company focused on immunology Business combination results in approximately $65 million in gross cash proceeds to support research and development initiatives and potential future acquisitions Combined company to trade on Nasdaq under ticker "ZURA" commencing March 21, 2023 Zura Bio Limited ("Zura"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the closing of its business combination with JATT Acquisition Corp, a special purpose acquisition company (NYSE:JATT) ("JATT"), on March 20, 2023. The business combination was

      3/21/23 6:13:00 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited

      JATT Acquisition Corp (NYSE:JATT) ("JATT"), a publicly traded special purpose acquisition company, today announced that its shareholders voted to approve its proposed business combination with Zura Bio Limited ("Zura"), a clinical-stage biotechnology company. At the extraordinary general meeting of JATT's shareholders, a total of 4,907,863 ordinary shares, or 95.5% of JATT's issued and outstanding ordinary shares as of February 16, 2023, the record date of the extraordinary general meeting, were present either in person or represented by proxy. Holders of 4,903,764 ordinary shares, or 99.9% of the votes cast at the meeting, voted in favor the business combination. At the closing of the bu

      3/16/23 4:17:00 PM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JATT Acquisition Corp Announces Planned Transfer of Listing to NASDAQ in Connection with its Proposed Business Combination with Zura Bio Limited

      JATT Acquisition Corp (NYSE:JATT, JATT.WS and JATT.U))) (the "Company"), a publicly-traded special purpose acquisition company, today announced that it will voluntarily transfer the listing of its Class A ordinary shares, public warrants and units from the New York Stock Exchange ("NYSE") to the Nasdaq Stock Market LLC ("Nasdaq") in connection with, and upon the closing of, the previously announced business combination (the "Business Combination") with Zura Bio Limited, a limited company incorporated under the laws of England and Wales ("Zura"). The Company expects that listing and trading of its listed securities on the NYSE will end at market close on March 20, 2023. The Class A ordinary

      3/13/23 9:28:00 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JATT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      2/14/24 4:39:38 PM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      2/14/24 9:02:53 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

      SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

      2/14/24 6:05:55 AM ET
      $JATT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care